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Abstract  
 
The immune system surveys the skin for keratinocytes (KC) infected by viruses or with 
acquired genetic damage. The mechanism by which T cells mediate KC elimination is 
however undefined.  We demonstrate here that antigen specific CD8 T cells can 
eliminate antigen bearing KC in vivo and inhibit their clonogenic potential in vitro 
independently of the effector molecules perforin and Fas-L.  In contrast, IFN-γ receptor 
expression on KC and T cells producing IFN-γ are each necessary and sufficient for in 
vitro inhibition of KC clonogenic potential.  Thus, antigen specific CTL may mediate 
destruction of epithelium expressing non-self antigen by eliminating KC with potential 
for self renewal via an IFN-γ dependent mechanism.  
 
 3 
Introduction  
 
 
Epithelial tumours comprise over 50% of human malignancies, and can express a range 
of viral and neo-self antigens.  Immunotherapy directed at tumour specific antigens has 
been mooted as therapy for epithelial squamous cancer (Urosevic and Dummer, 2002). 
Successful immunotherapy induces a range of antigen specific immune responses 
including CD8 effector T cells which are widely held to be responsible for control of 
tumour growth in vivo.  MHC class I restricted CD8 T cells induced by immunisation can 
induce regression of tumours expressing the E7 protein of human papillomavirus type 
16 (HPV16-E7) (Chen et al., 1991).  However when HPV16-E7 is presented by epithelial 
cells in skin, such immunisation is insufficient to eradicate antigen expressing cells 
(Dunn et al., 1997).    Cell death induced by CD8 T cells is generally evaluated in short 
term in vitro lysis assays, that most effectively demonstrate rapid lytic mechanisms 
based on perforin (Trapani and Smyth, 2002). In vivo, elimination of epithelial grafts, 
even from primed animals, occurs over several days or weeks. Thus, distinct effector 
mechanisms may be responsible for elimination of transplantable tumours versus 
elimination of antigen bearing skin. 
 
Alternate mechanisms for CD8 T cell mediated induction of epithelial cell death are well 
recognised. These include cytolysis following Fas/Fas-L interactions(Daehn et al., 2006) 
which is generally deemed to require 6-8 hours, and TNF- a and  TRAIL mediated 
differentiation and apoptosis(Basile et al., 2001). IFN-γ has also been shown to kill 
transformed epithelial cell lines in vitro (Konur et al., 2005).  We therefore decided to 
examine the effects of various T cell effector mechanisms on the clonogenic potential of 
non-malignant keratinocytes and on the survival of skin expressing non-self antigen only 
in keratinocytes.  This work distinguishes itself from most work on mechanism of skin 
allograft rejection in that non-self  antigens are expressed only by epithelial cells, and 
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not by antigen presenting cells, vascular or stromal cells, and can therefore be cross 
presented but not directly presented by these cells.     
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Results 
 
Requirements for rejection of skin grafts expressing antigen in keratinocytes 
 
We first defined the role of MHC class I restricted T cells in destruction of epithelium 
expressing antigen in keratinocytes (KC).  Skin from mice expressing a single MHC class I 
epitope of OVA (SIINFEKL) in KC from a keratin 14 promoter (K14-OVAp) was grafted 
onto mice expressing an irrelevant peptide, SIYRYYGL, as a transgene in the same 
expression cassette (K14-SIYp). Grafts from K14-OVAp animals were rejected at low 
frequency by untreated K14-SIYp animals (Fig 1 a), whereas grafts from non-transgenic 
animals were not rejected (data not shown).  Adoptive transfer of antigen specific 
spleen cells at the time of grafting increased the rate of graft rejection compared to 
untreated recipients although the increase did not reach statistical significance.  
However, adoptive transfer of antigen specific effector cells, combined with 
immunisation with ovalbumin, resulted in rejection of all K14-OVAp skin grafts by day 20 
post-grafting.  Thus, induction of MHC class I restricted effector cells by skin expressing 
a minimal CTL peptide in KC is inefficient.  However, MHC class I peptide restricted T 
cells activated by immunisation are sufficient to destroy epithelium expressing a single 
MHC class I restricted peptide in KC.  
 
To establish whether antigen in epithelial cells must necessarily be presented via MHC 
class I to enable effector function, skin from mice expressing membrane associated OVA 
protein from a keratin 5 promoter (K5-mOVA), and either expressing β2-microglobulin 
(b2m) or b2m deficient was grafted to naïve C57 recipients.   K5-mOVA b2m
+/+ grafts 
were rapidly rejected, whereas K5-mOVA b2m
-/- grafts generally survived (Fig 1 b).  Thus, 
KC expressing full length OVA and potentially presenting a diversity of MHC class I and II 
epitopes, in contrast to KC expressing a minimal OVA CTL epitope, can mediate priming 
of MHC Class I restricted T cells.  Taken together the data also show that antigen primed 
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MHC class I restricted T cells are necessary and sufficient to affect rejection of 
epithelium expressing antigen in KC.  
 
Perforin and Fas-L are not required for T cell mediated inhibition of keratinocyte colony 
formation in vitro 
 
To determine the mechanism by which MHC class I restricted CD8 T cells kill KC,  we 
assessed whether T cell lines could alter the ability of freshly isolated KC with colony 
forming potential to form colonies in vitro (Fig 2).   Primary cultures of KC pulsed with 
the minimal CTL epitope peptide of the E7 protein of HPV16 (RAHYNIVTF), or expressing 
E7 as a transgene, were cultured with RAHYNIVTF-specific CD8+ CTL lines, or, as a 
control, with an allospecific CTL line.    Allospecific CTL effectively killed EL4 and C57 KC 
targets, and inhibited colony formation of C57 KC (Fig 2 a).  Similarly E7 peptide-specific 
CTL exclusively killed peptide-pulsed EL4 cells, and inhibited colony formation of peptide 
pulsed and K14-E7 KC (Fig 2 b).   Killing of peptide pulsed EL4 cells and inhibition of KC 
colony formation  by E7 peptide specific CTL lines was then compared to inhibition with 
E7 specific CTL lines generated from C57 animals singly deficient in perforin, or Fas-L.   
Fas-L-/- CTL killed EL4 cells and inhibited KC colony formation as effectively as competent 
CTL.   Perforin-/- CTL were impaired in their ability to kill EL4 cells (Fig 2c), but neither 
perforin-/- CTL (Fig 2c) nor perforin CTL combined with antibody mediated FasL 
blockade inhibited KC colony formation.   Thus, inhibition of KC clonogenic potential in 
vitro requires neither Fas/Fas-L interactions nor perforin.  
 
Perforin and Fas-L are dispensable for rejection of E7 skin grafts 
 
The in vitro results described above demonstrate that killing of KC by MHC class I 
restricted T cells is not dependent on perforin.  To investigate the role of perforin or Fas-
L in rejection of skin grafts expressing HPV16-E7 as the target antigen, perforin-/- and 
Fas-L-/- mice carrying the β-chain of a T cell receptor specific for E7 as a transgene, were 
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bred from parent TCR transgenic animals.  Spleen cells from E7 TCR transgenic animals 
were transferred to syngeneic mice that were grafted with K14-E7 skin, and immunised 
with E7 protein.  Rejection of K14-E7 skin grafts, but not control C57 grafts was 
observed with Fas-L and perforin replete T cell lines (Fig 3 b), and  was also observed at 
similar frequency on animals receiving E7TCR spleen cells deficient in Fas-L or perforin 
(Fig 3 a).   Adoptive transfer of E7TCR spleen cells or E7TCR spleen cells deficient in 
either Fas-L or perforin to graft recipients, without concurrent E7 immunisation, or 
immunisation of graft recipients without concurrent cell transfer, did not induce graft 
rejection (Fig 3 a).  Taken together, these data indicate that expression of the cytotoxic 
effector molecules Fas-L and perforin by antigen specific CD8+ T cells, are not necessary 
for rejection of skin grafts expressing antigen in KC, replicating in vivo the findings for 
elimination of KC clonogenic potential by antigen specific T cell lines in vitro.  
 
Interferon-γ induces apoptosis of KC 
 
As perforin mediated lysis was not necessary for elimination of KC by CD8 T cells in vitro 
or of skin grafts in vivo, we examined whether a soluble factor produced by activated 
CD8 T cells might mediate impaired KC colony formation potential (Fig 4) .    KC were 
exposed in vitro to supernatants from T cells co-cultured with peptide pulsed, irradiated 
splenocytes or, as a control, T cells stimulated with irradiated splenocytes without 
added peptide.  Only supernatants from T cells co-cultured with splenocytes expressing 
cognate antigen could inhibit colony formation (Fig 4 a).  We hypothesised that IFN-γ, 
which is known to affect KC proliferation and differentiation, might be responsible for 
the observed inhibition of colony formation.   Addition of recombinant IFN-γ inhibited 
KC colony formation in dose dependent fashion, with peak inhibition observed with 
exposure of KC to 100ng IFN-γ/mL (Fig 4 b).  IFN-γ mediated colony inhibition could 
largely be reversed by addition of the pan-caspase inhibitor zVAD-fmk but not by 
addition of a control analogue zFA (Figure 4e).  T cell/splenocyte conditioned 
supernatants typically contained 6-7 µg/mL IFN-γ as assayed by ELISA, and were 
 8 
expected to contain other cytokines.  To determine whether IFN-γ was the primary 
cytokine responsible for inhibiting colony formation, neutralising antibody to IFN-γ or 
TNF-a was added to plated KC exposed to T cell conditioned supernatant.  Addition of 
anti-IFN-γ reduced maximal colony inhibition by the T cell conditioned supernatant in a 
dose dependent manner, whereas addition of control rat IgG or anti-TNF-a had no effect 
on colony inhibition induced by the T cell conditioned supernatant (Fig 4 c and d).  From 
these data we concluded that IFN-γ is the major soluble factor responsible for inhibition 
of colony formation by CTL conditioned supernatant. 
 
Interferon-γ from CTLs is necessary and sufficient to inhibit keratinocyte colony 
formation in vitro 
 
Taken together, these data show that exogenous IFN-γ at sufficient concentration 
inhibits KC colony formation.  To determine whether effector cell derived IFN-γ is 
necessary for inhibition of KC colony formation by antigen activated CTL, IFN-γ-/- CTLs 
and KC from interferon-γ receptor subunit-1 (IFN-γR1-/-) donors were used in the colony 
inhibition assay (Fig 5).  Killing of peptide pulsed EL4 cells and inhibition of KC colony 
formation by IFN-γ replete or deficient E7 specific CTL lines was compared.   IFN-γ-/- CTL 
were impaired in their ability to inhibit KC colony formation but not in their ability to kill 
EL4 cells (Fig 5 a and b).  Finally, CTL conditioned supernatant was added to C57 or IFN-
γR1-/- KC.  Colony formation from KC with intact signalling through their IFN-γR1 was 
inhibited by over 70% while colony formation by IFN-γR1-/- KCs was not impaired by the 
same supernatants (Fig 5 c).  Similarly, colony formation from C57 KC pulsed with E7 
peptide, and exposed to E7-specific T cells, was significantly inhibited (75%), while 
colony formation by KC not exposed to peptide and by peptide pulsed IFN-γR1-/- KC was 
not affected by co-culture with E7-peptide specific CTLs (Fig 5 d).  These data 
demonstrate that signalling through IFN-γR1 is necessary for both T cell mediated and 
CTL conditioned supernatant mediated inhibition of KC colony formation in vitro.   
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Discussion 
 
This study demonstrates that elimination of epithelium expressing non-self antigen only 
in keratinocytes requires CD8 T cells but does not require perforin, generally regarded 
as a sufficient effector mechanism for killing cultured cell lines in vitro and tumours in 
vivo. It shows further that elimination of KC with clonogenic potential concurrently 
expressing non-self antigens requires IFN-γ signalling to KC, and can be achieved by a 
sufficient concentration of IFN-γ in vitro.  
 
Prior studies of T cell effector function in skin have focussed on rejection of grafts 
presenting major or minor histocompatibility antigens(Mason, 1988), or on clearance of 
lytic epitheliotropic viruses(Doherty et al., 1997). Major histocompatibility allo-antigens, 
directly presented by antigen presenting cells in skin grafts, invoke strong and broad T 
effector responses, and either CD4 or CD8 T cells are able to effect graft 
rejection(Kobayashi et al., 1992), although CD4 cells are not necessary if CD8 cells are 
present(Haskova et al., 2000). Minor allo-antigens present on grafted epithelium, 
provided they are directly presented on bone marrow derived cells, can invoke strong 
immune responses and are also rejected by CD8 dependent mechanisms(Oukka et al., 
1997).  Keratinocytes are capable of processing and presenting antigen directly(Kim et 
al., 2009a), though transgenic antigens expressed in keratinocytes can also be cross 
presented by local CD103+ antigen presenting cells(Bedoui et al., 2009).  The precise 
effector mechanisms leading to skin graft rejection by MHC class I or II restricted T cells 
are undefined (Horner et al., 2008). However, as shown in this study, neighbouring 
grafts not displaying antigen are not damaged by immune destruction of antigen 
bearing grafts, and in an allophenic MHC class I restricted mouse model, cell destruction 
is specific to the epithelial cells presenting alloantigen and spares adjacent cells not 
presenting antigen (Singer and Rosenberg, 1988), suggesting that epithelial cell- effector 
T cell contact specifically determines cell death. In MHC class II restricted models of T 
 10 
cell killing, neither perforin, Fas ligand nor TNF-a are required, as was observed in the 
current study where killing is however clearly MHC class I restricted (Ito et al., 1999).  
 
CD8 effector cells have two broad and non-exclusive cell contact dependent effector 
mechanisms for killing target cells:  perforin/granzyme granule exocytosis, and ligation 
of TNF-a death receptor family members including Fas-L and TRAIL.  Multiphoton 
microscopy imaging suggests that in vivo, lytic mechanisms are much slower than those 
routinely observed in the in vitro cytotoxicity assays (Boissonnas et al., 2009) and are 
likely mediated by more than perforin mediated damage to the cell membrane.  While 
effector mechanisms targeted at vascular endothelium and antigen presenting cells may 
play a part in rejection of allo-grafts (Valujskikh et al., 2002), in epithelial tumours, as in 
the current grafting model, direct antigen presentation is limited to keratinocytes. 
Within the skin, the majority of keratinocytes are already terminally differentiated, with 
no self regeneration capacity.  Thus, only the epithelial stem cells, and cytokeratin 15 
expressing transit amplifying cells along the basement membrane, contribute to colony 
formation and are effective targets for immunotherapy (Murphy, 2007).   The partial 
response to caspase-inhibition likely reflects sensitivity of transient amplifying cells to 
IFN-γ mediated apoptosis whereas the epithelial stem cell compartment are resistant to 
Fas-mediated apoptosis via expression of the cell intrinsic caspases-8 inhibitor cFLIP 
(cellular Flice-inhibitory protein)(Armbruster et al., 2009).  Bone marrow derived stem 
cells, although susceptible to CD45 antibody mediated lysis,  generally  express low 
levels of MHC class I (Lampton et al., 2008;Kim et al., 2005) and are thus relatively 
resistant to conventional T cell lytic mechanisms, though susceptible to NK lysis by 
conventional lytic mechanisms (Moretta et al., 2003),and epithelial cells along the 
basement membrane of the hair follicle where stem and transit amplifying cells reside 
similarly express low levels of MHC (Paus et al., 1999) suggesting that they would be 
similarly resistant to lytic mechanisms requiring prolonged MHC class I restricted T cell 
interactions.   Thus, direct T cell/keratinocyte interactions are unlikely to be sufficient in 
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eliminating epithelium expressing antigen only in keratinocytes, as observed in practice 
in this and other studies we have conducted(Frazer, 2008). 
 
IFN-γ is a recognised promoter of differentiation of epithelial keratinocytes (Saunders 
and Jetten, 1994;Hancock et al., 1988), and of up regulation of MHC expression 
(Niederwieser et al., 1988) and antigen presentation by epithelial cells (Albanesi et al., 
1998).  In the current study, IFN-γ alone was sufficient to suppress the clonogenic 
potential of keratinocytes in vitro.  In vivo, up regulation of antigen presentation on 
keratinocytes by IFN-γ would increase the number of cells presenting antigen to T cells, 
leading to a positive feedback mechanism inducing more effector T cells locally to 
secrete IFN-γ (Wakim et al., 2008;Kim et al., 2009b), and thus force terminal 
differentiation of the locally susceptible stem cells.  Terminal differentiation  of stem 
cells and apoptosis of transient amplifying cells, potentially combine to eliminate 
epithelium expressing non-self antigen. This mechanism for elimination of antigen 
bearing epithelial tumours and skin expressing antigen from chronic viral infection is 
practically demonstrated by the benefits of IFN therapy for treatment of persistent HPV 
infection (Schneider et al., 1995), and of epithelial tumours (Takaku, 1987).  Whether 
these empiric interventions work through the proposed mechanism requires further 
study in animal models of these diseases. 
Materials and Methods 
 
Animals 
 
Inbred mouse strains used in this study, C57BL/6J (H-2b) mice, BALB/c (H-2d), FVB/n (H-
2q), were obtained from the Animal Resources Centre (Perth, Australia).  Inbred, 
transgenic mouse strains engineered to express their model antigens in epithelial cells 
included C57 mice transgenic for the HPV16-E7 oncoprotein expressed from the keratin 
(K)14 promoter (K14-E7 mice)(Frazer et al., 2001); C57 mice transgenic for minimal 
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peptide Ags, K14-erSIINFEKL.hGH (abbreviated K14-OVAp (McGargill et al., 2002) and 
K14-erSIYRYYGL.hGH(Stefanski et al., 2001), a gift from K.A. Hogquist, Univ. of 
Minnesota, USA; and C57 mice transgenic for a membrane-bound form of ovalbumin 
(K5-mOVA)(Azukizawa et al., 2003), a gift from S. Itami (Osaka University, Japan).  E7 
and OVA-specific spleen cells were obtained from E7T cell receptor (Narayan et al., 
2009) and Rag1-/- OVA T cell receptor(Hogquist et al., 1994) transgenic mice.  Mice 
deficient in expression of functional perforin, Fas-L, IFN-γ, IFN-γR1 or b2m were 
purchased from the Jackson Laboratory (Bar Harbor, ME) and bred locally.  MHC class I 
deficient K5-mOVA and perforin, functional Fas ligand or IFN-γ deficient E7TCR mice 
were obtained by inter-crossing F1 offspring of homozygous mutant mice and K5-mOVA 
or E7TCR transgenic mice respectively. 
 
Gender-matched mice at 6-12 weeks of age were used as effector cell donors and skin 
graft donors and recipients, and were maintained under conventional conditions in 
specific pathogen free holding rooms in the Princess Alexandra Hospital Biological 
Resources Facility.  Protocols were approved by the institutional animal ethics 
committee. 
 
Skin graft transplantation 
 
Whole-thickness skin was grafted as previously described (Matsumoto et al., 2004). 
Grafts were assessed as technically successful if adherent and vascularised on day 8. 
Individual grafts were considered rejected when no viable epidermis was evident.  
Grafts were observed at least twice weekly for the duration of experiments and 
classified as showing no evidence of rejection if grafts were intact at day 100.  
 
Combined active/passive immunotherapy for skin graft rejection 
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Combined active/passive immunotherapy was administered as previously described 
(Matsumoto et al., 2004).  Briefly, 5.0 x106 nucleated spleen cells from TCR transgenic 
mice or in vitro cultured CTLs were transferred to skin graft recipients on the day of 
grafting.  Where indicated, mice were immunised subcutaneously at the tail base with 
OVA protein (50 µg/ mouse; Sigma Aldrich, St Louis, MO) or a hexa-histidine HPV16-E7 
fusion protein (50 µg/ mouse), prepared in E. coli as previously described (Fernando et 
al., 1999).  Protein antigens were mixed with 10 µg QuilA (Iscotec AB, Lulea, Sweden) 
prior to injection.   
 
Generation of cytotoxic T lymphocyte lines  
 
HPV16-E7 peptide specific CTL lines were prepared as previously described except that 
spleens were collected 7 days post immunisation rather than 3 weeks (Leggatt et al., 
2002).  Cells were used at day 7 to 10 post stimulation.  Allo-antigen specific CTLs were 
induced in BALB/c mice by a single subcutaneous immunisation with 2x107 irradiated 
C57 spleen cells.  Donor spleens were collected after 7-10 days and cultured as 
described above except the allogeneic stimulator cells were irradiated in the absence of 
exogenous peptide.  Anti-HA (influenza) peptide specific CTLs were generated exactly as 
described(Shanker et al., 2009).   
 
Cell-free CTL supernatant was collected from perforin deficient CTLs which had been 
stimulated with antigen (E7-peptide pulsed, irradiated syngeneic splenocytes) 7 days 
previously.    The supernatant was clarified by centrifugation at 3000 rpm for 10 min at 
4oC. Supernatants collected from the same CTL line over successive weeks were pooled, 
filtered through 0.22 μm filter, and stored at -80oC.  CTL conditioned supernatant was 
then supplemented into the test wells with total volume maintained at 2 mL per well.  
Control supernatant was collected from parallel cultures of perforin deficient CTLs 
expanded as above except peptide was omitted from the irradiated stimulator cells. 
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Cytotoxicity assay 
 
51Chromium release cytotoxicity assays with cultured CTL lines and conventional or KC 
targets were undertaken, and per cent specific lysis was calculated, as described 
previously (Leggatt et al., 2002).   
 
 Keratinocyte Colony Inhibition Assay 
 
Primary murine epithelial keratinocytes (KC) were isolated as previously described 
(Leggatt et al., 2002), and 15-20,000 KC were added to each well of a 6-well tissue 
culture plate previously coated with rat tail collagen.  Plates were then incubated for 3 
days to allow adherence and colony formation to commence.  Where indicated rm-IFN-γ 
(BD-Pharmingen, batch specific activity 1.1x108 U/mg), the pan-caspase inhibitor zVAD-
fmk (Promega, Madison, WI) or control analogue zFA-fmk (ICN Pharmaceuticals Inc., 
Aurora, OH) was added into the culture media from day 4 to day 7.  Bovine serum 
albumin (Sigma Aldrich) was used as a control for non-specific effects of protein 
addition. Soluble E7-peptide was added where indicated on assay day 3.  After 24 hours, 
free peptide was removed by gentle washing prior to addition of CTL at different 
effector to target ratios (E:T).  The assays were typically incubated for a further 3 days at 
37C.  Additional manipulations included blockade of IFN-γ (biotinylated, clone R4-6A2, 
BD Pharmingen),  FasL (clone MFL4, BD Pharmingen), or TNF-a (clone G281-2626, BD 
Pharmingen) with purified, neutralising monoclonal antibodies which were added to 
wells daily.  Affinity purified rat IgG1 (eBioscience, San Diego, CA) was used as a control 
treatment. 
 
When distinct colonies were visible in “no treatment” wells, assays were terminated and 
the KC colonies visualized by staining with Coomassie Blue (0.1%w/v Brilliant blue dye 
(Sigma Aldrich) in 10% v/v acetic acid and 90% v/v methanol) for 2min at room 
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temperature.  Stain was then aspirated from the wells and colonies were washed with 
destain buffer (10% v/v acetic acid; 30% v/v methanol; 60% v/v water) until distinct 
colonies were evident.  Plates were allowed to air dry.  Percentage reduction in colony 
number was calculated as: %reduction in colony counts = (mean count (no treatment) – 
mean count (test))/ mean count (no treatment) x100. 
 
Statistics 
 
Specific lysis and colony inhibition data are expressed as mean ± SD. The statistical 
significance of differences was determined by 2-tailed, unpaired t-test using GraphPad 
Prism (version 4.0) software.  Kaplan-Meier plots were used to analyse skin graft 
survival, and a log rank test was used to examine the statistical significance of 
differences in the survival curves.  Differences with P<0.05 were considered significant. 
 16 
  
Conflict of interest 
The authors have no conflicting financial interests. 
 
Acknowledgements 
This work was supported by a program grant from the National Health and Medical 
Research Council of Australia, and grants from the Cancer Council Australia, the 
Australian Cancer Research Foundation and the Cancer Research Institute (New York). 
RDK was supported by funds from the University of Queensland Graduate School, 
Cancer Council (Qld) and the British Council- Researcher Exchange Program.  IHF was 
supported by a Queensland Government Premier’s fellowship.  We thank C. Maxim, R. 
Coulter and K. Fagan for their assistance with the mice used in this study and for 
excellent animal care.  
 17 
Figure Legends 
 
Figure 1 Skin grafts expressing a minimal CTL epitope are sensitive to rejection.   
a Skin from K14-OVAp mice was grafted onto K14-SIYp recipients that were, at the time 
of grafting, otherwise untreated (■, n=13), given 5x106 Rag1-/-OVA TCR splenocytes by 
adoptive transfer (AT only, ▼ , n=9), or given splenocytes and additionally  immunised 
with OVA (AT+IM, ○ , n=15).  Graft survival was subjected to Kaplan – Meyer analysis: 
survival of K14-OVAp skin grafts on AT + IM recipients compared to untreated or AT only 
recipients was significantly shorter ( P<0.0001).  
b Skin from β2-microglobulin -/- mice with (, n=16) or without co-expression of 
membrane anchored OVA (, n=8) or skin from K5-mOVA mice (■, n=9) was grafted 
onto C57 recipients.  Graft survival was subjected to Kaplan – Meyer analysis: survival of 
β2-microglobulin +/+ K5-mOVA grafts was significantly shorter (P<0.005) than survival of 
the other grafts.  
 
 
Figure 2 T cell mediated inhibition of KC growth.  T cell lines were tested for ability to 
lyse cell lines in a 4h chromium-release assay (left panel) and to inhibit colony formation 
from primary KC (right panel).   
a H-2d anti-H-2b T cell line at 10:1 E:T ratio.  Left panel: lysis of P815 cells (H-2d), EL4 cells 
(H-2b) and primary KC (H-2b).    Right panel: inhibition of colony formation from H-2d, H-
2b or H-2q KC.   
b H-2b/E7 peptide specific T cell line . Left panel: lysis of EL4 cells, with or without 1µM 
E7 peptide, 20:1 E:T ratio.  Right panel: inhibition of colony formation from KC with or 
without 1μm E7 peptide, or from K14-E7 KC, 25:1 E:T ratio.  
c H-2b/E7 peptide specific T cell lines from C57, perforin-/-  or Fas-L-/- mice at 5:1 E:T 
ratio. Left panel: lysis of EL4 cells with or without 1µM E7 peptide.  Right panel inhibition 
of colony formation from H-2b KC with or without 1μm E7 peptide.  
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d  H-2b anti-HA (influenza) peptide specific CTLs from C57 or Perforin -/- mice at 5:1 E/T 
ratio.  Inhibition of colony formation from H-2b KC with or without 1μm HA peptide.  
All results mean + SD and representative of between two and four independent assays. 
 
**P<0.01, ***P<0.001, ****P<0.0001, n.s. P>0.05. 
 
Figure 3  Rejection of human papillomavirus type-16 (HPV16) E7 skin grafts 
independent of perforin and Fas-L   a  HPV16-E7 skin was grafted  to C57 recipients 
immunised with E7 protein (IM only ◊, n=14), adoptively  transferred with E7TCR 
splenocytes (AT only▼, n=14) or immunised with E7 protein and adoptively transferred 
with E7TCR (AT+IM ○, n=35), Fas-L-/- E7TCR(■, n=20) or perforin-/- E7TCR(∆, n=15) 
splenocytes.   Kaplan-Meier survival curves are shown. b HPV16-E7 skin grafts were 
transplanted onto C57 recipients immunised with E7 protein and adoptively transferred 
with E7 peptide-specific CTL lines.  CTL lines were C57 (○, n=12), Fas-L-/- (■, n=14) or 
perforin -/- (∆, n=17).  Kaplan Meier survival curves are shown. 
 
Figure 4 IFN-γ is sufficient to inhibit KC colony formation in vitro.  Primary KC were 
treated with CTL conditioned supernatant (a, c and d) or recombinant mouse IFN-γ (b 
and e) from day 4 to 7 of culture.  Where indicated, the pan-caspase inhibitor zVAD-fmk 
(20µM final)(e) or purified neutralising monoclonal antibodies against IFN-γ (c) or TNF-a 
(d) were also added.  Results are shown as percentage reduction in colony numbers 
compared with untreated KC, and expressed as mean + SD. Experiment representative 
of 2 independent assays.  **P<0.01, n.s. P>0.05 treatment versus IFN-γ only. 
 
 
Figure 5 IFN-γ is necessary for KC colony inhibition in vitro.  E7 peptide specific T cells 
were generated from C57 or IFN-γ-/- mice and were added to a EL4 and EL4 pulsed with 
1µM E7 peptide targets in a 4h chromium-release assay (E:T 5:1) or b C57 KC and C57 KC 
pulsed with 1µM E7 peptide targets in a colony inhibition assay (E:T 6.2:1).  KC with or 
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without surface expression of IFN-γ receptor were c used as targets in a colony 
inhibition assay with addition of CTL conditioned supernatant or d pulsed with 1µM E7 
peptide and used as targets in a colony inhibition assay with E7 peptide specific T cells 
as effectors (E:T 5:1).  Results are expressed as mean + SD of triplicate wells from one 
representative experiment of 2 independent assays.  *P<0.05 
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